Dendreon Corporation

The firm represented FUJIFILM Diosynth Biotechnologies in connection with Dendreon’s chapter 11 case and the transfer of FDB’s contract with Dendreon to a purchaser of Dendreon’s business. FDB's predecessor manufactured a component antigen for a cancer-fighting drug distributed by Dendreon.

Our website uses cookies to enhance site navigation, analyze site usage, and assist in our marketing efforts. By continuing to browse this website, you agree to our Privacy Policy.